Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Avidity Biosciences reported a quarterly loss of $1.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.05, and a significant increase from a loss of $0.65 per share a year ago, indicating a negative earnings surprise of -20.95% [1] - The company achieved revenues of $12.48 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 399%, and showing substantial growth from $2.34 million in the same quarter last year [2] - Avidity Biosciences shares have increased by approximately 140.2% year-to-date, significantly outperforming the S&P 500's gain of 14.4% [3] Financial Performance - Over the last four quarters, Avidity Biosciences has surpassed consensus EPS estimates only once, while it has topped revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$1.00 on revenues of $2.65 million, and for the current fiscal year, it is -$4.30 on revenues of $8.79 million [7] Industry Context - Avidity Biosciences operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Avidity Biosciences' stock may be influenced by the overall industry trends, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]